NCT03277261 - Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) | Biotech Hunter

Enrollment

549

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

July 23, 2020

Study Completion Date

November 6, 2020

Conditions

Relapsing Multiple Sclerosis (RMS)

Interventions

BIOLOGICAL

Ublituximab

Administered as an IV infusion.

DRUG

Teriflunomide

Film-coated tablets administered orally.

DRUG

Oral Placebo

Administered orally.

DRUG

IV Placebo

Administered as an IV infusion.

Trial Locations (14)

14226

TG Therapeutics RMS Investigational Trial Site, Amherst

33136

TG Therapeutics RMS Investigational Trial Site, Miami

37064

TG Therapeutics RMS Investigational Trial Site, Franklin

37922

TG Therapeutics RMS Investigational Trial Site, Knoxville

43081

TG Therapeutics RMS Investigational Trial Site, Westerville

48201

TG Therapeutics RMS Investigational Trial Site, Detroit

60062

TG Therapeutics RMS Investigational Trial Site, Northbrook

66160

TG Therapeutics RMS Investigational Trial Site, Kansas City

75246

TG Therapeutics RMS Investigational Trial Site, Dallas

78681

TG Therapeutics RMS Investigational Site, Round Rock

90808

TG Therapeutics RMS Investigational Trial Site, Long Beach

91105

TG Therapeutics RMS Investigational Trial Site, Pasadena

92001

TG Therapeutics RMS Investigational Trial Site, Carlsbad

94305

TG Therapeutics RMS Investigational Trial Site, Stanford

All Listed Sponsors

lead

TG Therapeutics, Inc.

INDUSTRY